Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GE Healthcare invests in cardiac diagnostics

This article was originally published in The Gray Sheet

Executive Summary

Firm's "Healthymagination Fund" enters into a $5 million strategic alliance with CardioDx to co-develop diagnostics for cardiovascular disease, GE announces May 13. CardioDx's flagship product, Corus CAD, a non-invasive genomic test to assess the potential for coronary artery disease, launched in the U.S. last fall (1"The Gray Sheet" Sept. 7, 2009). The deal marks the $250 million Healthymagination Fund's first investment since its formation in October 2009 (2"The Gray Sheet" Nov. 2, 2009). The equity fund targets three broad areas for investment: diagnostics, health care information technology and life sciences

You may also be interested in...

CardioDx Launches Gene Test For Obstructive Coronary Disease

CardioDx is gradually rolling out its Corus CAD gene expression test, which quantifies the likelihood of obstructive coronary artery disease in patients with stable chest pain and no previous history of cardiac disease

US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework

Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts